Viewray: ViewRay and VieCure Announce Strategic Collaboration to Accelerate Adoption of Personalized Cancer Care

Date: Wednesday, 1 April 2020

CLEVELAND, April 1, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today a strategic collaboration with VieCure, an artificial intelligence (AI) informatics company with a leading point-of-care clinical decision support platform and a comprehensive electronic medical record (EMR) in oncology. The collaboration is designed to drive personalized care and treatment to patients by educating oncology practices on both companies' precision oncology solutions.

Through the alliance, clinicians will have access to ViewRay's MRIdian MRI-guided radiation therapy system and VieCure's VCurePrecision™ EMR platform. VCurePrecision provides a real-time decision-support system that combines clinical knowledge with patient data to assist oncologists in generating personalized treatment plans and managing a patient's care throughout his or her cancer therapy. ViewRay's MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue and tumors while radiation is delivered. MRIdian also offers a powerful gating feature that automatically controls the radiation beam throughout each treatment, turning it off if the tumor moves outside of the targeted treatment area. The combination of MRIdian and VCurePrecision offers a formidable comprehensive precision oncology solution.

"Through our collaboration with VieCure, we gain access to a wider network of oncologists and healthcare systems to offer a comprehensive cancer treatment and records integration solution," said Paul Ziegler, Senior Vice President of Sales and Marketing at ViewRay. "Both VieCure and ViewRay are leaders within their field – bringing clinicians a state-of-the-art AI-powered patient data system and the world's first MRI-guided radiation therapy system. The ability to deliver these world-class solutions together is a real benefit to oncology practices interested in advancing personalized treatment to improve patient outcomes."

"Oncologists are embracing the paradigm shift toward data-driven precision medicine, but they face a myriad of clinical workflow and content-related challenges," said Fred Ashbury, Ph.D., Chief Scientific Officer at VieCure. "Our platform combines patient data with leading scientific knowledge in radiation oncology, systemic therapy and surgical oncology, and generates individualized treatment prescriptions throughout the patient's diagnosis and care journey. We are excited to deliver even better insights to the multidisciplinary clinical team and the participating radiation oncologists, medical physicists, therapists and treatment planners who will use our A.I. enabled smart EMR."

VieCure's oncology-specific and AI-enabled VCurePrecision platform is aimed at both private practice cancer centers and large provider organizations as a point-of-care solution to collect, curate, streamline and manage diagnostic and treatment options ranging from molecular test results through patient-reported outcomes. The platform also incorporates AI clinical rules to personalize standard of care to the specific characteristics of an individual's cancer.

Currently 34 MRIdian systems are installed at hospitals around the world, where they are being used to treat a wide variety of solid tumors and are the focus of numerous ongoing research initiatives. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. More than 8,000 patients have been treated with MRIdian. For a list of treatment centers, please visit: